Dowell, S. F. & Ho, M. S. Seasonality of infectious diseases and severe acute respiratory syndromewhat we dont know can hurt us. Lancet Infect. Dis. 4, 704708 (2004). <\/p>\n
Article Google Scholar <\/p>\n
Bygbjerg, I. C. Double burden of noncommunicable and infectious diseases in developing countries. Science 337, 14991501 (2012). <\/p>\n
Article Google Scholar <\/p>\n
Baker, R. E. et al. Infectious disease in an era of global change. Nat. Rev. Microbiol. 20, 193205 (2022). <\/p>\n
Article Google Scholar <\/p>\n
Dong, E., Du, H. & Gardner, L. An interactive web-based dashboard to track COVID-19 in real time. Lancet Infect. Dis. 20, 533534 (2020). <\/p>\n
Article Google Scholar <\/p>\n
Mosier, D. A. Bacterial pneumonia. Vet. Clin. North. Am. Food Anim. Pract. 13, 483493 (1997). <\/p>\n
Article Google Scholar <\/p>\n
Bradley, B. T. & Bryan, A. Emerging respiratory infections: the infectious disease pathology of SARS, MERS, pandemic influenza, and Legionella. Semin. Diagn. Pathol. 36, 152159 (2019). <\/p>\n
Article Google Scholar <\/p>\n
Shao, X. et al. An innate immune system cell is a major determinant of species-related susceptibility differences to fungal pneumonia. J. Immunol. 175, 32443251 (2005). <\/p>\n
Article Google Scholar <\/p>\n
Zhou, P. & Shi, Z.-L. SARS-CoV-2 spillover events. Science 371, 120122 (2021). <\/p>\n
Article Google Scholar <\/p>\n
Abraham, E. et al. Consensus conference definitions for sepsis, septic shock, acute lung injury, and acute respiratory distress syndrome: time for a reevaluation. Crit. Care Med. 28, 232235 (2000). <\/p>\n
Article Google Scholar <\/p>\n
DiSilvio, B. et al. Complications and outcomes of acute respiratory distress syndrome. Crit. Care Med. 42, 349361 (2019). <\/p>\n
Google Scholar <\/p>\n
Li, K. et al. Middle East respiratory syndrome coronavirus causes multiple organ damage and lethal disease in mice transgenic for human dipeptidyl peptidase 4. J. Infect. Dis. 213, 712722 (2016). <\/p>\n
Article Google Scholar <\/p>\n
Singh, A. Eliciting B cell immunity against infectious diseases using nanovaccines. Nat. Nanotechnol. 16, 1624 (2021). <\/p>\n
Article Google Scholar <\/p>\n
Saunders, K. O. et al. Neutralizing antibody vaccine for pandemic and pre-emergent coronaviruses. Nature 594, 553559 (2021). <\/p>\n
Article Google Scholar <\/p>\n
Su, Z. et al. Bioresponsive nano-antibacterials for H2S-sensitized hyperthermia and immunomodulation against refractory implant-related infections. Sci. Adv. 8, eabn1701 (2022). <\/p>\n
Article Google Scholar <\/p>\n
Chaudhary, N., Weissman, D. & Whitehead, K. A. mRNA vaccines for infectious diseases: principles, delivery and clinical translation. Nat. Rev. Drug. Discov. 20, 817838 (2021). <\/p>\n
Article Google Scholar <\/p>\n
Wareing, M. D. & Tannock, G. A. Live attenuated vaccines against influenza; an historical review. Vaccine 19, 33203330 (2001). <\/p>\n
Article Google Scholar <\/p>\n
Skountzou, I. et al. Salmonella flagellins are potent adjuvants for intranasally administered whole inactivated influenza vaccine. Vaccine 28, 41034112 (2010). <\/p>\n
Article Google Scholar <\/p>\n
Ellebedy, A. H. et al. Contemporary seasonal influenza A (H1N1) virus infection primes for a more robust response to split inactivated pandemic influenza A (H1N1) virus vaccination in ferrets. Clin. Vaccine Immunol. 17, 19982006 (2010). <\/p>\n
Article Google Scholar <\/p>\n
Ninomiya, A. Intranasal administration of a synthetic peptide vaccine encapsulated in liposome together with an anti-CD40 antibody induces protective immunity against influenza A virus in mice. Vaccine 20, 31233129 (2002). <\/p>\n
Article Google Scholar <\/p>\n
Roy, S. et al. Viral vector and route of administration determine the ILC and DC profiles responsible for downstream vaccine-specific immune outcomes. Vaccine 37, 12661276 (2019). <\/p>\n
Article Google Scholar <\/p>\n
Mielcarek, N., Alonso, S. & Locht, C. Nasal vaccination using live bacterial vectors. Adv. Drug. Deliv. Rev. 51, 5569 (2001). <\/p>\n
Article Google Scholar <\/p>\n
Wu, Y. et al. A recombinant spike protein subunit vaccine confers protective immunity against SARS-CoV-2 infection and transmission in hamsters. Sci. Transl. Med. 13, eabg1143 (2021). <\/p>\n
Article Google Scholar <\/p>\n
Smith, T. R. F. et al. Immunogenicity of a DNA vaccine candidate for COVID-19. Nat. Commun. 11, 2601 (2020). <\/p>\n
Article Google Scholar <\/p>\n
Narasimhan, M. et al. Serological response in lung transplant recipients after two doses of SARS-CoV-2 mRNA vaccines. Vaccines 9, 708 (2021). <\/p>\n
Article Google Scholar <\/p>\n
Berkhout, B., Verhoef, K., van Wamel, J. L. B. & Back, N. K. T. Genetic instability of live, attenuated human immunodeficiency virus type 1 vaccine strains. J. Virol. 73, 11381145 (1999). <\/p>\n
Article Google Scholar <\/p>\n
Cevik, M. COVID-19 vaccines: keeping pace with SARS-CoV-2 variants. Cell 184, 50775081 (2021). <\/p>\n
Article Google Scholar <\/p>\n
KhalajHedayati, A., Chua, C. L. L., Smooker, P. & Lee, K. W. Nanoparticles in influenza subunit vaccine development: immunogenicity enhancement. Influenza Other Resp. Vir. 14, 92101 (2020). <\/p>\n
Article Google Scholar <\/p>\n
Kim, C. G., Kye, Y.-C. & Yun, C.-H. The role of nanovaccine in cross-presentation of antigen-presenting cells for the activation of CD8+ T cell responses. Pharmaceutics 11, 612 (2019). <\/p>\n
Article Google Scholar <\/p>\n
Silva, A. L., Soema, P. C., Sltter, B., Ossendorp, F. & Jiskoot, W. PLGA particulate delivery systems for subunit vaccines: linking particle properties to immunogenicity. Hum. Vaccines Immunother. 12, 10561069 (2016). <\/p>\n
Article Google Scholar <\/p>\n
Huang, J. et al. Nasal nanovaccines for SARS-CoV-2 to address COVID-19. Vaccines 10, 405 (2022). <\/p>\n
Article Google Scholar <\/p>\n
Hussain, A. et al. mRNA vaccines for COVID-19 and diverse diseases. J. Control. Rel. 345, 314333 (2022). <\/p>\n
Article Google Scholar <\/p>\n
Meng, Q. et al. Capturing cytokines with advanced materials: a potential strategy to tackle COVID19 cytokine storm. Adv. Mater. 33, 2100012 (2021). <\/p>\n
Article Google Scholar <\/p>\n
Hotchkiss, R. S., Coopersmith, C. M., McDunn, J. E. & Ferguson, T. A. The sepsis seesaw: tilting toward immunosuppression. Nat. Med. 15, 496497 (2009). <\/p>\n
Article Google Scholar <\/p>\n
van de Veerdonk, F. L. et al. A guide to immunotherapy for COVID-19. Nat. Med. 28, 3950 (2022). <\/p>\n
Article Google Scholar <\/p>\n
Wykes, M. N. & Lewin, S. R. Immune checkpoint blockade in infectious diseases. Nat. Rev. Immunol. 18, 91104 (2018). <\/p>\n
Article Google Scholar <\/p>\n
Florindo, H. F. et al. Immune-mediated approaches against COVID-19. Nat. Nanotechnol. 15, 630645 (2020). <\/p>\n
Article Google Scholar <\/p>\n
Jiang, S., Zhang, X., Yang, Y., Hotez, P. J. & Du, L. Neutralizing antibodies for the treatment of COVID-19. Nat. Biomed. Eng. 4, 11341139 (2020). <\/p>\n
Article Google Scholar <\/p>\n
Nasiruddin, M., Neyaz, Md. K. & Das, S. Nanotechnology-based approach in tuberculosis treatment. Tuberc. Res. Treat. 2017, 112 (2017). <\/p>\n
Google Scholar <\/p>\n
Abani, O. et al. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet 397, 16371645 (2021). <\/p>\n
Article Google Scholar <\/p>\n
The REMAP-CAP Investigators. Interleukin-6 receptor antagonists in critically ill patients with Covid-19. N. Engl. J. Med. 384, 14911502 (2021). <\/p>\n
Article Google Scholar <\/p>\n
Kozlov, M. Omicron overpowers key COVID antibody treatments in early tests. Nature https:\/\/doi.org\/10.1038\/d41586-021-03829-0<\/a> (2021). <\/p>\n Roback, J. D. & Guarner, J. Convalescent plasma to treat COVID-19: possibilities and challenges. JAMA 323, 15611562 (2020). <\/p>\n Article Google Scholar <\/p>\n Nguyen, P. T. N., Nho Van Le, Nguyen Dinh, H. M., Nguyen, B. Q. P. & Nguyen, T. V. A. Lung penetration and pneumococcal target binding of antibiotics in lower respiratory tract infection. Curr. Med. Res. Opin. 38, 20852095 (2022). <\/p>\n Article Google Scholar <\/p>\n Qiao, Q. et al. Nanomedicine for acute respiratory distress syndrome: the latest application, targeting strategy, and rational design. Acta Pharm. Sin. B 11, 30603091 (2021). <\/p>\n Article Google Scholar <\/p>\n Duan, Y., Wang, S., Zhang, Q., Gao, W. & Zhang, L. Nanoparticle approaches against SARS-CoV-2 infection. Curr. Opin. Solid. State Mater. Sci. 25, 100964 (2021). <\/p>\n Article Google Scholar <\/p>\n Doroudian, M., MacLoughlin, R., Poynton, F., Prina-Mello, A. & Donnelly, S. C. Nanotechnology based therapeutics for lung disease. Thorax 74, 965976 (2019). <\/p>\n Article Google Scholar <\/p>\n Yang, H. et al. Amino acid-dependent attenuation of Toll-like receptor signalling by peptide-gold nanoparticle hybrids. ACS Nano 9, 67746784 (2015). <\/p>\n Article Google Scholar <\/p>\n Gao, Y., Dai, W., Ouyang, Z., Shen, M. & Shi, X. Dendrimer-mediated intracellular delivery of fibronectin guides macrophage polarization to alleviate acute lung injury. Biomacromolecules 24, 886895 (2023). <\/p>\n Article Google Scholar <\/p>\n Liu, F.-C. et al. Use of cilomilast-loaded phosphatiosomes to suppress neutrophilic inflammation for attenuating acute lung injury: the effect of nanovesicular surface charge. J. Nanobiotechnol. 16, 35 (2018). <\/p>\n Article Google Scholar <\/p>\n Kou, M. et al. Mesenchymal stem cell-derived extracellular vesicles for immunomodulation and regeneration: a next generation therapeutic tool? Cell Death Dis. 13, 580 (2022). <\/p>\n Article Google Scholar <\/p>\n Liu, W. et al. Recent advances of cell membrane-coated nanomaterials for biomedical applications. Adv. Funct. Mater. 30, 2003559 (2020). <\/p>\n <\/p>\n Read more: Dowell, S. F. Continue reading
\nImmunoregulatory nanomedicine for respiratory infections - Nature.com<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"